ARQT - Arcutis gets FDA approval for Zoryve for atopic dermatitis
2024-07-09 17:14:02 ET
More on Arcutis Biotherapeutics
- Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
- Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript
- Arcutis Biotherapeutics: Betting Big On Zoryve
- Arcutis says FDA still working on action letter for roflumilast
- Arcutis Biotherapeutics surges 22% on Q1 beats